近90%患者缓解的强生口服多肽疗法;默沙东达近5亿美元口服多肽疗法合作 TIDES周报

动脉网
19 Apr

强生口服多肽疗法3期临床试验结果积极,近90%的青少年患者皮肤症状清除。默沙东与Cyprumed合作开发口服多肽药物。TIDES疗法领域迎来系列进展,包括其他多肽疗法的临床试验结果。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10